Hillrom to acquire Breathe Tech and its wearable ventilator for $130M

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio. (Kritchanut/iStock/Getty Images Plus/Getty Images)

Hillrom has moved to pick up former Fierce 15 winner Breathe Technologies, maker of a wearable ventilator for people with lung conditions such as chronic obstructive pulmonary disease. 

The $130 million cash deal would see Breathe’s Life2000 non-invasive air system added to Hillrom’s respiratory care portfolio, broadening the company’s reach in COPD as well as interstitial lung disease, restrictive thoracic disorder and rehabilitation following a lung transplant.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The ventilator unit, which weighs about a pound, can be worn on a belt or waistband and has a four-hour battery life. It can be connected to a separate, stationary compressor for use inside the home, with tubing up to 50 feet long, or used alone outside the home while connected to an alternate pressure source.

RELATED: FierceMedicalDevices’ 2014 Fierce 15 | Breathe Technologies

"The acquisition of a highly differentiated, wearable non-invasive ventilation technology provides an exciting growth platform that utilizes our direct Respiratory Care commercial channel and business model," Hillrom President and CEO John Groetelaars said in a statement. 

Breathe's Life2000 ventilator
and compressor. (Breathe)

RELATED: Hillrom debuts new handheld telehealth eye camera for diabetic retinopathy screening

"This transaction represents another example of our plan to strategically deploy capital with a disciplined approach toward higher-growth and higher-margin businesses by expanding into the disruptive new category of non-invasive ventilation," Groetelaars added. 

Hillrom expects to close the deal during the fourth quarter of its 2019 fiscal year. The other products in its respiratory portfolio include a variety of airway clearance systems, including wearable and acute care versions, as well as nebulizer support.

Suggested Articles

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

Novartis has teamed up with smart inhaler developer Propeller Health to co-package and ship its digital medication-tracking platform.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.